PSMA PET Combined With MRI for the Detection of PCa

PHASE3RecruitingINTERVENTIONAL
Enrollment

204

Participants

Timeline

Start Date

August 18, 2025

Primary Completion Date

June 30, 2026

Study Completion Date

November 30, 2026

Conditions
PCAProstate CancerProstatic NeoplasmPSMA PETDiagnostic ImagingElevated PSAPositron Emission TomographyProstate BiopsyCarcinoma of the Prostate
Interventions
DRUG

68Ga-PSMA-11

The radioconjugate 68Ga-PSMA-11 is composed of a human PSMA-targeting ligand peptide conjugated via the acyclic radiometal chelator, N, N'-bis \[2-hydroxy-5-(carboxyethyl)benzyl\] ethylenediamine-N, N'-diacetic acid (HBED-CC) to the radioisotope Gallium68 ( 68Ga); which binds to PSMA on the surface of cells expressing PSMA, including malignant prostate cancer cells, which usually overexpress PSMA. 68Ga is a β+ (beta) ray emitting radionuclide that allows precise imaging via PET.

Trial Locations (1)

3055

RECRUITING

Australian Prostate Centre, Melbourne N.

All Listed Sponsors
collaborator

Telix Innovations S.A.

UNKNOWN

lead

Telix Pharmaceuticals (Innovations) Pty Limited

INDUSTRY